Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Payables (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Payables data on record, last reported at $13.2 million in Q4 2025.

  • For Q4 2025, Payables rose 180.55% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $13.2 million, up 180.55%, while the annual FY2025 figure was $13.2 million, 180.55% up from the prior year.
  • Payables reached $13.2 million in Q4 2025 per ACRS's latest filing, up from $9.2 million in the prior quarter.
  • Across five years, Payables topped out at $13.2 million in Q4 2025 and bottomed at $4.2 million in Q2 2021.
  • Average Payables over 5 years is $8.3 million, with a median of $8.2 million recorded in 2022.
  • Peak YoY movement for Payables: tumbled 47.17% in 2024, then surged 180.55% in 2025.
  • A 5-year view of Payables shows it stood at $10.0 million in 2021, then rose by 3.67% to $10.4 million in 2022, then decreased by 14.23% to $8.9 million in 2023, then plummeted by 47.17% to $4.7 million in 2024, then soared by 180.55% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $13.2 million in Q4 2025, $9.2 million in Q3 2025, and $8.8 million in Q2 2025.